Clinical Trials and Outcomes
Proof-of-Concept Phase 2 trial showing that Metformin reduces the metabolic and clinical complications of long-term glucocorticoid medications in patients with no diabetes. Patients receiving Metformin fared significantly better in metabolic, bone, thrombotic parameters and had significantly fewer infections and hospital stays. As Glucocorticoids are used for a wide spectrum of indications, including inflammatory diseases, these data could have an immediate large impact affecting up to 3% of the adult population in the UK and elsewhere. A collaborative study led by Professor Márta Korbonits.
- Metformin: the white knight fighting corticosteroid side-effects. Commentary in the Lancet Diabetes and Endocrinology on Clinical Trial led by Korbonits & colleagues: Metformin: the white knight fighting corticosteroid side-effects.
- Clinical Trials and Outcomes
- Websites for Referring Patients with Rare Endocrine Disorders for Genetic Diagnoses & Helpful Patient Information
- REF Impact Statements and Gene Panels
- Pioneering Research and Treatments in Paediatric and Adult Endocrinology
- Informed and influenced Guidelines for Management of Endocrine and Cardiovascular Patients
- Award-winning MSc in Clinical Endocrinology and Diabetes
- Editorial Boards and Recent Journal Covers